Trademark: MEPACT 1028390
Word
MEPACT
ID
1028390
Trademark Type
Word
Status
Registered: Renewal due
Application Date
05 November 2004
Registration Date
05 November 2004
Renewal Date
05 November 2024
Owner(s)
Service
Spruson & Ferguson
Goods and Services:
Class 5:
Chemical preparations for medical or veterinary use, including particularly muramyl peptides and muramyl tripeptides, muramyl tripeptide phosphatidyl ethanolamine (MTP-PE),N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine -2-(1,2-dipalmitoyl-sn-glycero-3- hydroxyphosphoryloxy)-ethylamide, hexopyranose and formulations of muramyl peptides, particularly liposomal formulations, pharmaceutically acceptable forms of muramyl peptides, pharmaceutically acceptable salts of muramyl peptides, all of these products being used for anti-cancer therapy, antiviral therapy, neoplasia and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy; pharmaceutical preparations, particularly for anti-cancer and antiviral therapies, neoplasia, and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy
Chemical preparations for medical or veterinary use, including particularly muramyl peptides and muramyl tripeptides, muramyl tripeptide phosphatidyl ethanolamine (MTP-PE),N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine -2-(1,2-dipalmitoyl-sn-glycero-3- hydroxyphosphoryloxy)-ethylamide, hexopyranose and formulations of muramyl peptides, particularly liposomal formulations, pharmaceutically acceptable forms of muramyl peptides, pharmaceutically acceptable salts of muramyl peptides, all of these products being used for anti-cancer therapy, antiviral therapy, neoplasia and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy; pharmaceutical preparations, particularly for anti-cancer and antiviral therapies, neoplasia, and pathologies induced by chemotherapy, particularly mucositis, myelosuppression, peripheral neuropathy